Skip to content
Biodatica
Start free

Daiichi Sankyo Co., Ltd.

Beijing, California

OncologyPhase IIIListed · DSNKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

3w agoTrial registeredJun 26, 2026Source filing (opens the source filing in a new tab)

Momentum

83no change

Momentum 83 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Mar 15, 2021

    Tenosynovial Giant Cell Tumor · COMPLETED · sponsor: Daiichi Sankyo Co., Ltd. · A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

    ClinicalTrials.gov · NCT04703322 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jan 7, 2021

    Hepatotoxicity, Tenosynovial Giant Cell Tumor · RECRUITING · sponsor: Daiichi Sankyo · A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

    ClinicalTrials.gov · NCT04635111 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Sep 25, 2020

    Tenosynovial Giant Cell Tumor · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo Co., Ltd. · A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

    ClinicalTrials.gov · NCT04488822 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources